ArticleFrontiers in oncology2026
Plasma proteome-wide Mendelian randomization reveals multi-ancestry drug targets for gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) exhibits marked epidemiological differences between European (EUR) and East Asian (EAS) populations, with significantly higher incidence rates in EAS. Circulating proteins represent promising drug targets; however, most proteomic studies have focused primarily on EUR ancestry, leaving EAS-specific targets largely underexplored. This study aims to identify ancestry-specific plasma protein targets for GC using Mendelian randomization (MR). Methods: We employed Mendelian randomization (MR) and colocalization approaches to assess the putative causal effects of plasma proteins on GC risk across diverse populations. Specifically, we examined proteins in EUR and EAS populations. Subsequent single-cell RNA sequencing and molecular docking were conducted to identify cellular expression patterns and potential therapeutic compounds. Finally, experiments were conducted to verify the newly discovered drug target. Results: Our analyses revealed four significant protein targets in the EUR population (SLURP1, ANGPTL3, NME4, ANXA10) and nine in the EAS population (ICAM5, SMOC1, PSCA, SATB1, SCRG1, PTPRB, ISLR2, NCR3LG1, SELE) associated with GC susceptibility. These drug targets are mainly expressed in epithelial cells, and Pit mucous cells in gastric tumor tissue. Experimental validation indicated significant downregulation of NME4 and upregulation of ICAM5 in GC cell lines and tissue samples, suggesting potential tumor-suppressive and oncogenic functions, respectively. Moreover, molecular docking identified seven repurposable drugs, with digoxin demonstrating cross-ancestry therapeutic potential. Conclusion: Our findings delineate 13 ancestry-specific protein targets, including five novel candidates, thereby enhancing our understanding of GC pathogenesis. This study underscores the importance of ancestral diversity in informing drug development strategies for GC. Future research should focus on validating these targets and exploring their functional mechanisms further to translate these findings into clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.